Leeds, UK, January 4, 2022, – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic Products (LBPs), a novel class of drug derived
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
We are paying close attention to the AQSE Growth Market after CEO Zak Mir announced Lift Global Ventures signalled their Intention to Float. CEO Zak Mir has been a big part
4D pharma presents microbiome analyses from Phase II clinical trial of Blautix® for IBS-C and IBS-D at Gastro 2021
Zak Mir takes a charting perspective on some of the most followed stocks on the London market. Today’s selection includes Amur, Caracal, Chill, Cornish, 4D, East Imperial, Genedrive, Open Orphan,
Zak Mir takes a charting perspective on some of the most followed small caps on the London market. Today’s selection includes 4D, e-Therapeutics, Caracal, Heiq, Mkango, Nuformix, Oberon, Rambler, Transense,
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
Zak Mir takes a technical analysis perspective on some of the most followed small caps on the London market. Today’s selection includes Anglesey, Brighton Pier, Caracal, Cizzle, 4D, Greatland, Getech,
Zak Mir takes a technical perspective on some of the most followed small caps on the London market. Today’s selection includes Abingdon, Aura, Bisichi, Cellular, Contango, Deltic, 4D, Falanx, Hemogenyx,
Turning to the wider small-cap market, the AIM All-Share was down 1.2% over the week, which meant it underperformed the FTSE 100, which more or less kept its head above
Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
